Temporal changes of angiopoietins and Tie2 expression in rat lungs after monocrotaline-induced pulmonary hypertension.

Angiogenic factors such as vascular endothelial growth factor (VEGF) are implicated in pulmonary hypertension (PH). However, the pathway of angiogenic factor-mediated pathologic angiogenesis in PH remains unclear. In this study, we evaluated the temporal expression of angiopoietin (Ang) 1, Ang2, and their receptor (Tie2) as well as VEGF, endothelial nitric oxide synthase (eNOS), inducible NOS (iNOS), and heme oxygenase 1 (HO1) in the monocrotaline-induced PH model. Histologic evaluation showed pathologic vascular remodeling in the arteries of lung sections 1 wk after monocrotaline treatment. Protein levels of Ang1, Ang2, eNOS, iNOS, HO1, and VEGF were increased 1 wk after monocrotaline treatment but Tie2 protein levels were decreased 2 wk afterward. These results suggest that Ang2 mediates vascular remodeling in PH by decreasing Tie2 expression. Therefore, the Ang-Tie2 system may play a role in the pathophysiology of PH.

[1]  K. Alitalo,et al.  Signaling and Functions of Angiopoietin-1 in Vascular Protection , 2006, Circulation research.

[2]  J. Pittet,et al.  Angiopoietin-2: Modulator of Vascular Permeability in Acute Lung Injury? , 2006, PLoS medicine.

[3]  G. Hospers,et al.  A review on pro- and anti-angiogenic factors as targets of clinical intervention. , 2006, Pharmacological research.

[4]  D. Christiani,et al.  Excess Circulating Angiopoietin-2 May Contribute to Pulmonary Vascular Leak in Sepsis in Humans , 2006, PLoS medicine.

[5]  Sung Hyun Kim,et al.  COMP-Ang1: a designed angiopoietin-1 variant with nonleaky angiogenic activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Weitzman,et al.  A new animal model for pulmonary hypertension based on the overexpression of a single gene, angiopoietin-1. , 2004, The Annals of thoracic surgery.

[7]  P. Thistlethwaite,et al.  Induction of pulmonary hypertension by an angiopoietin 1/TIE2/serotonin pathway , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Black,et al.  Expression of VEGF and its receptors Flt-1 and Flk-1/KDR is altered in lambs with increased pulmonary blood flow and pulmonary hypertension. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[9]  D. Stewart,et al.  Protective Role of Angiopoietin-1 in Experimental Pulmonary Hypertension , 2003, Circulation research.

[10]  Richard A. Lang,et al.  Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Sugawara,et al.  Heme oxygenase-1 reduces murine monocrotaline-induced pulmonary inflammatory responses and resultant right ventricular overload. , 2002, Antioxidants & redox signaling.

[12]  Thomas N. Sato,et al.  Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF) , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Kasza,et al.  Heme oxygenase activity modulates vascular endothelial growth factor synthesis in vascular smooth muscle cells. , 2002, Antioxidants & redox signaling.

[14]  J. Tonn,et al.  Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. , 2002, The Journal of clinical investigation.

[15]  P. Thistlethwaite,et al.  Human angiopoietin gene expression is a marker for severity of pulmonary hypertension in patients undergoing pulmonary thromboendarterectomy. , 2001, The Journal of thoracic and cardiovascular surgery.

[16]  P. Kuo,et al.  Pulmonary Expression of iNOS and HO-1 Protein Is Upregulated in a Rat Model of Prehepatic Portal Hypertension , 2000, Digestive Diseases and Sciences.

[17]  S. Rich,et al.  Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". , 2000, Circulation.

[18]  M. Humbert,et al.  Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. , 2000, American journal of respiratory and critical care medicine.

[19]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[20]  G. Yancopoulos,et al.  In Situ Expression of Angiopoietins in Astrocytomas Identifies Angiopoietin-2 as an Early Marker of Tumor Angiogenesis , 1999, Experimental Neurology.

[21]  G. Yancopoulos,et al.  New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF , 1999, Oncogene.

[22]  G. Yancopoulos,et al.  Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. , 1999, Genes & development.

[23]  K. Alitalo,et al.  Is angiopoietin-2 necessary for the initiation of tumor angiogenesis? , 1998, The American journal of pathology.

[24]  J. Isner,et al.  Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. , 1998, Circulation research.

[25]  H. Kimura,et al.  Role of EDRF in pulmonary circulation during sustained hypoxia. , 1998, Journal of cardiovascular pharmacology.

[26]  M. Dewhirst,et al.  Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. , 1997, Circulation research.

[27]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[28]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[29]  B. Walker,et al.  Selective upregulation of arterial endothelial nitric oxide synthase in pulmonary hypertension. , 1997, The American journal of physiology.

[30]  Pamela F. Jones,et al.  Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.

[31]  J. Rossant,et al.  The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. , 1995, The EMBO journal.

[32]  R. Johns,et al.  Distribution of NOS in normoxic vs. hypoxic rat lung: upregulation of NOS by chronic hypoxia. , 1994, The American journal of physiology.

[33]  M. Gertsenstein,et al.  Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. , 1994, Genes & development.

[34]  H. Schnürch,et al.  Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage. , 1993, Development.

[35]  N. Voelkel,et al.  PAF antagonists inhibit monocrotaline-induced lung injury and pulmonary hypertension. , 1991, Journal of applied physiology.

[36]  D. Buff.  Primary pulmonary hypertension. , 1987, Annals of internal medicine.

[37]  Kuhn La.  Idiopathic pulmonary hypertension. , 1960, Journal of the Mount Sinai Hospital, New York.

[38]  M. Dewhirst,et al.  Functional significance of Tie2 signaling in the adult vasculature. , 2004, Recent progress in hormone research.

[39]  H. Esumi,et al.  Reciprocal regulation between nitric oxide and vascular endothelial growth factor in angiogenesis. , 2003, Acta biochimica Polonica.

[40]  G. Yancopoulos,et al.  The angiopoietins: Yin and Yang in angiogenesis. , 1999, Current topics in microbiology and immunology.